Regeneron Pharmaceuticals(REGN.US) Officer Sells US$6.85 Million in Common Stock
J&J Submits FDA Application for Myasthenia Gravis Drug Nipocalimab
Form 144 | Regeneron Pharmaceuticals(REGN.US) Officer Proposes to Sell 6.85 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Aug 28, $Regeneron Pharmaceuticals(REGN.US)$ Officer Christopher Fenimore intends to sell 5,680 shares of its common stock on Aug 28, with a total market value of
Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?
Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma
Evaluating Regeneron Pharmaceuticals Against Peers In Biotechnology Industry
Ready for Fed Rate Cuts? Biotech's Potential to Watch
Regeneron (REGN.US) lymphoma therapy Ordspono approved by the European Commission.
According to the press release, this is the first time odronextamab has received approval from global regulatory agencies for the treatment of this patient population.
Regeneron Gets European OK of Lymphoma Drug Ordspono
Express News | Ordspono™ (Odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
Is the rebound fading? Goldman Sachs: Hedge funds are selling stocks at the fastest pace in more than two years.
In August, 'smart money' is selling global equities at the fastest pace since March 2022, with the most net selling in North America. Hedge funds are skeptical of the sustainability of the stock market rebound, and geopolitical concerns continue to be worrying. The 'fly' of the economic situation may soon hit the glass windshield.
Regeneron Highlights Scientific Innovation And Leadership In Respiratory Disease Management At ERS 2024, Featuring Dupixent And Itepekimab
Express News | Regeneron - Data From Landmark Phase 3 Trials for Dupixent in Copd Reinforce Exacerbation Reduction, Improvement in Lung Function Compared to Placebo
Ordspono (Odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Latest Dupixent (Dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
Regeneron Pharma Is Maintained at Overweight by Piper Sandler
Regeneron Pharmaceuticals Analyst Ratings
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,242
Does Regeneron Pharmaceuticals (NASDAQ:REGN) Have A Healthy Balance Sheet?
Express News | Regeneron Pharmaceuticals Inc : Piper Sandler Raises Target Price to $1242 From $1166